GILD vs MRNA
Gilead Sciences and Moderna, side by side.
Prices and company dataas of yesterday's close
- GILDBuy more18%
Gilead Sciences' report on Oct 29 beat profit forecasts by 18%, and it pays a 2% dividend that it has raised for 10 years in a row.
- MRNASell some130%
Moderna's report on Nov 6 beat profit forecasts by 130%, but the stock rose 11% over the past month, in step with other biotech stocks (up 12%).
Percent return
- GILD+41.91%
- MRNA+841.65%
Nov 11, 2025 to Nov 11, 2026
Where they differ
- Company size: GILD $165B, MRNA $23.7B.
- Sales growth, 1 yr: GILD +6.5%, MRNA +13%. MRNA is ahead.
- Profit per $1 of sales: GILD 38¢, MRNA −81¢. GILD is ahead.
- Cash minus debt: GILD −$18.3B, MRNA +$3.75B. MRNA is ahead.
- Price change, 1 yr: GILD +42%, MRNA +842%. MRNA is ahead. S&P 500 +12%.
- How much the price swings: GILD 28%, MRNA 196%. GILD is ahead.
| Measure | GILDGilead Sciences | MRNAModerna |
|---|---|---|
| Price and returns | ||
| Price | $169.74 | $248.80 |
| Today | Best in this row: −0.66% | −0.81% |
| 1 month | Best in this row: +12.28% | +10.53% |
| 3 months | +25.72% | Best in this row: +310.76% |
| This year | +40.77% | Best in this row: +743.30% |
| 1 year | +41.91% | Best in this row: +841.65% |
| 5 years | Best in this row: +200.78% | +10.13% |
| From 52-week high | −2.7% | −7.5% |
| How much it swings (90 days) | Best in this row: 28% | 196% |
| Valuation | ||
| Market value | $165B | $23.7B |
| Price vs last year's earnings | 18.1× | – |
| Price vs next year's expected earnings | 20.0× | – |
| Price vs earnings, adjusted for growth | 1.46× | – |
| Price to sales | Best in this row: 6.7× | 44.4× |
| Price vs cash it brings in | 15.0× | – |
| Company value vs operating profit | 15.4× | – |
| Growth | ||
| Revenue growth, 1 year | +6.5% | Best in this row: +13.1% |
| Revenue growth a year, last 3 years | Best in this row: +2.6% | −53.4% |
| Earnings per share growth, last year | Best in this row: +55.0% | +6.6% |
| Earnings per share growth expected next year | Best in this row: +1290.9% | +44.2% |
| Profitability | ||
| Kept from sales after making the product | Best in this row: 80.0% | −42.0% |
| Kept as operating profit | Best in this row: 38.2% | −80.8% |
| Kept as final profit | Best in this row: −12.5% | −110.5% |
| Kept as spare cash | Best in this row: 44.5% | −78.0% |
| Profit on shareholders' money | Best in this row: −22.4% | −34.5% |
| Profit on all money put in | Best in this row: 36.8% | −46.3% |
| Balance sheet | ||
| Net cash (cash minus debt) | −$18.3B | Best in this row: $3.75B |
| Debt for each $1 of shareholders' money | 2.02× | Best in this row: 0.62× |
| Short-term assets per $1 of bills due | 1.38× | Best in this row: 3.62× |
| Dividend yield | 1.97% | – |
| Our readPro | ||
| Our call | Buy more | Sell some |
| Why | Gilead Sciences' report on Oct 29 beat profit forecasts by 18%, and it pays a 2% dividend that it has raised for 10 years in a row. | Moderna's report on Nov 6 beat profit forecasts by 130%, but the stock rose 11% over the past month, in step with other biotech stocks (up 12%). |
| Where the price sits | in the full report | in the full report |
| Our overall score (out of 100) | Best in this row: 73 | 47 |
| Our value score | Best in this row: 91 | 50 |
| Our growth score | Best in this row: 70 | 48 |
| Our quality score | Best in this row: 90 | 37 |
| Our price trend score | 48 | Best in this row: 50 |
| Earnings and analysts | ||
| Analyst consensus | Buy | Hold |
| To average analyst target | Best in this row: +1.9% | −41.6% |
| Average analyst target | $172.95 | $145.38 |
| Analysts rating it a buy | Best in this row: 79% | 17% |
| Buy ratings added, 3 months | Best in this row: 0 | −1 |
| Analysts covering | 22 | 20 |
GILD: our only Buy more, with wider profit margins
Our pick of these: Gilead Sciences
Keeps 38.2% of sales as operating profit, vs −80.8%
GILD 38.2%, MRNA −80.8%.+1.9% to the average analyst target, vs −41.6%
GILD +1.9%, MRNA −41.6%.79% of analysts rate it a buy, vs 17%
GILD 79%, MRNA 17%.Where it loses: MRNA has faster sales growth, +13.1% vs +6.5%
Cover this stock to see the full report
The call, its reasons and what would change it are free for everyone. The price zones, the whole brief and how the call has moved come with covering a stock. Use one of your three covered slots, or go Pro for every stock.
Prices as of yesterday, 3:59 PM ET. A view, not advice.